Nanog Cancer Research Results

Nanog, human hNanog protein coded by the NANOG gene: Click to Expand ⟱
Source:
Type:
NANOG is a transcription factor in embryonic stem cells (ESCs); Nanog is one of the key transcription factors, along with Oct4 and Sox2, involved in maintaining pluripotency in embryonic stem cells.’ Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.; Nanog's role in metastasis includes promoting the survival and proliferation of cancer stem cells in secondary sites, aiding their ability to establish new tumors.
Nanog is often expressed in cancer stem cells (CSCs).
High levels of Nanog expression have been correlated with increased tumor aggressiveness, metastasis, and the ability to evade apoptosis (programmed cell death).
BC, Breast Cancer: Click to Expand ⟱
Breast Cancer
Scientific Papers found: Click to Expand⟱
4821- ASTX,    Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53
- in-vitro, BC, SkBr3 - in-vitro, BC, BT20 - in-vitro, BC, T47D
Apoptosis↑, CSCs↓, OCT4↓, Nanog↓, TumCP↓,
5721- BF,    Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway
- in-vitro, BC, NA
CSCs↓, TumCCA↑, cMyc↓, cycD1/CCND1↓, CDK4↓, MMP↓, Casp↑, CD133↓, CD44↓, ALDH1A1↓, Nanog↓, OCT4↓, SOX2↓, Wnt↓, β-catenin/ZEB1↓, EGFR↓,
420- CUR,    Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
Vim↓, Fibronectin↓, β-catenin/ZEB1↓, E-cadherin↓, CD44↑, CD24↓, OCT4↓, Nanog↓, SOX2↓,
1860- dietFMD,  Chemo,    Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
- in-vitro, BC, SUM159 - in-vitro, BC, 4T1
PI3K↑, Akt↑, mTOR↑, CDK4↑, CDK6↑, hyperG↓, TumCG↓, TumVol↓, Casp3↑, BG↓, eff↑, eff∅, PKA↓, KLF5↓, p‑GSK‐3β↑, Nanog↓, OCT4↓, KLF2↓, eff↑, ROS↑, BIM↑, ASK1↑, PI3K↑, Akt↑, mTOR↑, CDK1↓, CDK4↑, CDK6↑, eff↑,
6844- EVO,    Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70
- vitro+vivo, Lung, A549 - in-vitro, Colon, HCT116 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
Apoptosis↑, CSCs↓, TumVol↓, *toxicity↓, HSP70/HSPA5↓, OCT4↓, Nanog↓, cl‑PARP↑, cl‑Casp3↑,
54- QC,    Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways
- in-vitro, BC, MCF7
EMT↓, E-cadherin↑, Vim↓, MMP2↓, NOTCH1↓, PI3K/Akt↓, PI3k/Akt/mTOR↓, p‑Akt↓, EZH2↓, H3K27ac↓, TumCCA↑, CSCs↓, CDK1↓, CycB/CCNB1↓, Bcl-xL↓, Bcl-2↓, Nanog↓, H3↓,
4995- Sal,    Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway
- vitro+vivo, BC, MDA-MB-231
ALDH↓, Nanog↓, OCT4↓, SOX2↓, CSCs↓, tumCV↓, cycD1/CCND1↓, P21↑, TumCG↓, CD44↓, Apoptosis∅,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

hyperG↓, 1,   ROS↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

KLF5↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,   PI3K/Akt↓, 1,   PI3k/Akt/mTOR↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 2,   p‑Akt↓, 1,   Apoptosis↑, 2,   Apoptosis∅, 1,   ASK1↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   BIM↑, 1,   Casp↑, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,   H3↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK4↓, 1,   CDK4↑, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   ALDH1A1↓, 1,   CD133↓, 1,   CD24↓, 1,   CD44↓, 2,   CD44↑, 1,   CSCs↓, 5,   EMT↓, 1,   p‑GSK‐3β↑, 1,   H3K27ac↓, 1,   mTOR↑, 2,   Nanog↓, 7,   NOTCH1↓, 1,   OCT4↓, 6,   PI3K↑, 2,   SOX2↓, 3,   TumCG↓, 2,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↓, 1,   E-cadherin↑, 1,   Fibronectin↓, 1,   KLF2↓, 1,   MMP2↓, 1,   PKA↓, 1,   TumCP↓, 1,   Vim↓, 2,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 3,   eff∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BG↓, 1,   EGFR↓, 1,   EZH2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

TumVol↓, 2,  
Total Targets: 65

Pathway results for Effect on Normal Cells:


Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: Nanog, human hNanog protein coded by the NANOG gene
1 Astaxanthin
1 Bufalin/Huachansu
1 Curcumin
1 diet FMD Fasting Mimicking Diet
1 Chemotherapy
1 Evodiamine
1 Quercetin
1 salinomycin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:212  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page